About Sarah McCall

This author has not yet filled in any details.
So far Sarah McCall has created 80 blog entries.

Zolgensma® Data Shows Rapid, Significant, Clinically Meaningful Benefit in SMA, Including Prolonged Event-free Survival, Motor Milestone Achievement and Durability, Now Up to 5 Years Post-dosing

AveXis, a Novartis company, announced a one-time infusion of Zolgensma® (onasemnogene abeparvovec-xioi) showed rapid, significant, and clinically meaningful therapeutic benefit in patients with spinal muscular atrophy (SMA) across a range of studies, including ...

2020-09-09T10:17:09-05:00March 24th, 2020|Front Page News, Research|
Go to Top